D-甘油-D-古洛-庚糖酸 | 87-74-1

• 分子结构分类: 有机化合物 - 有机氧化合物
• 中文名称: D-甘油-D-古洛-庚糖酸
• 中文别名: 5'-氟-2'-甲基-2-三氟甲基二苯甲酮
• 英文名称: D-glucoheptonic acid
• 英文别名: glucoheptonic acid；α-glucoheptonic acid；heptagluconic acid；(2R,3R,4S,5R,6R)-2,3,4,5,6,7-hexahydroxyheptanoic acid
• CAS: 87-74-1
• 化学式: C₇H₁₄O₈
• 分子量: 226.183
• InChiKey: KWMLJOLKUYYJFJ-VFUOTHLCSA-N

物化性质

• 熔点：
  145-148°
• 比旋光度：
  D20 -56.0° (shows mutarotation)

计算性质

• 辛醇/水分配系数(LogP)：
  -4
• 重原子数：
  15
• 可旋转键数：
  6
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.86
• 拓扑面积：
  159
• 氢给体数：
  7
• 氢受体数：
  8

反应信息

• 作为反应物：
  描述：

  D-甘油-D-古洛-庚糖酸 在 盐酸 、 硫酸 作用下， 以 甲醇 为溶剂， 反应 2.0h， 生成
  参考文献：
  名称：

  d-艾多糖、d-艾杜糖醛酸和来自 d-葡萄糖的 d-艾多糖酸通过七碳糖

  摘要：

  从碘庚糖酸中实际合成非常稀有的糖d-idose和d-idose、d-iduronic和d-idonic酸的稳定结构单元只需要异丙叉保护，Shing硅胶支持的C6高碘酸盐裂解庚酸的 -C7 键，以及 C1 和/或 C6 的选择性还原。d-艾多糖是所有己醛糖中最不稳定的，而且是一种稳定的前体，可以储存，然后在非常温和的条件下转化为 d-艾多糖，很容易制备。

  DOI：

  10.3390/molecules24203758
• 作为产物：
  描述：

  葡萄糖 生成 D-甘油-D-古洛-庚糖酸
  参考文献：
  名称：

  Hudson; Hartley; Purves, Journal of the American Chemical Society, 1934, vol. 56, p. 1249

  摘要：

  DOI：
• 作为试剂：
  描述：

  sodium [99Tc]pertechnetate 、 2-((2-(2-((2-(6-(dimethylamino)pyridin-3-yl)benzo[d]thiazol-6-yl)oxy)ethoxy)ethyl)(2-((2-mercaptoethyl)amino)ethyl)amino)ethane-1-thiol 在 D-甘油-D-古洛-庚糖酸 作用下， 以 乙醇 为溶剂， 反应 0.34h， 生成 2-((2-(2-((2-(6-(dimethylamino)pyridin-3-yl)benzo[d]thiazol-6-yl)oxy)ethoxy)ethyl)(2-((2-mercaptoethyl)amino)ethyl)amino)ethane-1-thiol ^99mTc(V) oxide
  参考文献：
  名称：

  Oligoethyleneoxy-Modified ^99mTc-Labeled β-Amyloid Imaging Probes with Improved Brain Pharmacokinetics for Single-Photon Emission Computed Tomography

  摘要：

  An oligoethyleneoxy linker was introduced for conjugation between Tc-99m/Re-bis(aminoethanethiol) (BAT) and beta-amyloid (A beta) binding scaffolds. Rhenium complexes exhibited high to moderate binding affinity to A beta(1-42) aggregates and efficient fluorescent staining to A beta plaques in brain tissue. After radiolabeling, the Tc-99m-labeled probes revealed improved brain pharmacokinetics in normal ICR mice. Probe [Tc-99m]15 with potent binding affinity (K-i = 13.4 nM) and the highest initial brain uptake (2.10% ID/g at 2 min) in normal ICR mice was evaluated further. In vitro autoradiography showed specific labeling of A beta plaques by [Tc-99m]15 in transgenic (Tg) mouse brain tissue. Ex vivo autoradiography further demonstrated its efficient labeling of A beta plaques in a living Tg mouse. In vivo single photon emission computed tomography (SPECT)/CT imaging in six rhesus monkeys revealed remarkably improved brain uptakes (1.94-2.63% ID within 20 min) of [Tc-99m]15, making it highly potential to be used in humans for A beta plaques imaging in the brain.

  DOI：

  10.1021/acs.jmedchem.7b01834

文献信息

• 一种茚达特罗中间体的制备方法
  申请人：四川海思科制药有限公司

  公开号：CN107868045A

  公开（公告）日：2018-04-03

  本发明公开了茚达特罗中间体5‑[(R)‑2‑(5,6‑二乙基‑茚满‑2‑基氨基)‑1‑羟基‑乙基]‑8‑苄氧基‑(1H)‑喹啉‑2‑酮盐的一种合成方法，该方法包括将8‑苄氧基‑5‑(R)‑环氧乙烷基‑(1H)‑喹啉‑2‑酮与2‑氨基‑(5，6‑二乙基)‑茚满在酮类溶剂中进行偶联反应，得到5‑[(R)‑2‑(5,6‑二乙基‑茚满‑2‑基氨基)‑1‑羟基‑乙基]‑8‑苄氧基‑(1H)‑喹啉‑2‑酮，然后经有机酸处理得到目标中间体的结晶等步骤。本发明的合成方法减少了偶联副产物的产生，大大提高了目标中间体收率，降低了生产成本。
• Simultaneous dual isotope imaging of cardiac perfusion and cardiac inflammation
  申请人：——

  公开号：US20030003049A1

  公开（公告）日：2003-01-02

  The present invention provides novel diagnostic compositions comprising a radiolabeled LTB4 binding agent and a radiolabeled perfusion imaging agent, diagnostic kits comprising such compositions, and methods of concurrent imaging in a mammal comprising administering a radiolabeled LTB4 binding agent and a radiolabeled perfusion imaging agent, and concurrently detecting the radiolabeled LTB4 binding agent bound at the LTB4 receptor and the radiolabeled perfusion imaging agent.

  本发明提供了包括放射标记的LTB4结合剂和放射标记的灌注成像剂的新型诊断组合物，包括这种组合物的诊断试剂盒，以及在哺乳动物中进行同时成像的方法，包括给予放射标记的LTB4结合剂和放射标记的灌注成像剂，并同时检测结合在LTB4受体上的放射标记的LTB4结合剂和放射标记的灌注成像剂。
• Radiopharmaceuticals for imaging infection and inflammation
  申请人：——

  公开号：US20030124053A1

  公开（公告）日：2003-07-03

  The present invention provides novel radiopharmaceuticals useful for the diagnosis of infection and inflammation, reagents and kits useful for preparing the radiopharmaceuticals, methods of imaging sites of infection and/or inflammation in a patient, and methods of diagnosing diseases associated with infection or inflammation in patients in need of such diagnosis. The radiopharmaceuticals bind in vivo to the leukotriene B4 (LTB4) receptor on the surface of leukocytes which accumulate at the site of infection and inflammation. The reagents provided by this invention are also useful for the treatment of diseases associated with infection and inflammation.

  本发明提供了用于诊断感染和炎症的新型放射性药物，用于制备这些放射性药物的试剂和工具包，用于在患者体内成像感染和/或炎症部位的方法，以及用于诊断需要此类诊断的患者中与感染或炎症相关的疾病的方法。这些放射性药物在体内与在感染和炎症部位聚集的白细胞表面的白三烯B4（LTB4）受体结合。本发明提供的试剂还可用于治疗与感染和炎症相关的疾病。
• [EN] 1,4-DISUBSTITUTED ISOQUINILONE DERIVATIVES AS RAF-KINASE INHIBITORS USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISEASES<br/>[FR] DERIVES D'ISOQUINILONE 1,4-DISUBSTITUES EN TANT QU'INHIBITEURS DE RAF-KINASE UTILES POUR LE TRAITEMENT DE MALADIES PROLIFERANTES
  申请人：NOVARTIS AG

  公开号：WO2005028444A1

  公开（公告）日：2005-03-31

  This invention relates to compounds of formula (I) wherein the variable substituents are described herein. The compounds are useful for the treatment of conditions and diseases characterized by an aberrant MAP kinase signaling pathway, such as cancer.

  本发明涉及式（I）化合物，其中变量取代基在本文中描述。这些化合物可用于治疗由异常的MAP激酶信号通路引起的疾病和症状，如癌症。
• Phthalazine derivatives for treating inflammatory diseases
  申请人：——

  公开号：US20030013718A1

  公开（公告）日：2003-01-16

  The invention relates to the treatment of an inflammatory disease, especially an inflammatory rheumatoid or rheumatic disease, and/or pain with an inhibitor of the activity of VEGF receptor tyrosine kinase of the formula I, 1 wherein r is 0 to 2, n is 0 to 3 R 1 and R 2 a) are independently in each case a lower alkyl; b) together form a bridge of subformula I*, 2 wherein the bond is achieved via the two terminal C atoms and m is 0 to 4, or c) together form a bridge of subformula I**, 3 wherein one or two of the ring members T 1 , T 2 , T 3 and T 4 are nitrogen, and the others are in each case CH, and the bond is achieved via atoms T 1 and T 4 ; G is —C(═O)—, —CHF—, —CF 2 —, lower alkylene, C 2 -C 6 alkenylene, lower alkylene or C 3 -C 6 alkenylene substituted by acyloxy or hydroxy, —CH 2 —O—, —CH 2 —S—, —CH 2 —NH—, —CH 2 —O—CH 2 —, —CH 2 —S—CH 2 —, —CH 2 —NH—CH 2 —, oxa (—O—), thia (—S—), imino (—NH—), —CH 2 —O—CH 2 —, —CH 2 —S—CH 2 — or —CH 2 —NH—CH 2 —; A, B, D, E and T are independently N or CH subject to the proviso that at least one and not more than three of these radicals are N; Q is lower alkyl, lower alkoxy or halogen; R a and R a ′ are each independently H or lower alkyl; X is imino, oxa, or thia; Y is hydrogen, aryl, heteroaryl, or unsubstituted or substituted cycloalkyl; and Z is mono- or disubstituted amino, halogen, alkyl, substituted alkyl, hydroxy, etherified or esterified hydroxy, nitro, cyano, carboxy, esterified carboxy, alkanoyl, carbamoyl, N-mono- or N,N-disubstituted carbamoyl, amidino, guanidino, mercapto, sulfo, phenylthio, phenyl lower alkylthio, alkylphenylthio, phenylsulfinyl, phenyl-lower alkylsulfinyl, alkylphenylsulfinyl, phenylsulfonyl, phenyl-lower alkylsulfonyl, alkylphenylsulfonyl, or (alternatively or, in a broader aspect of the invention, in addition) selected from the group consisting of ureido, halo-lower alkylthio, halo-lower alkansulfonyl, pyrazolyl, lower-alkyl pyrazolyl and C 2 -C 7 alkenyl; wherein—if more than 1 radical Z (m≧2) is present—the substituents Z are selected independently from each other; and wherein the bonds characterized in subformula I* by a wavy line are either single or double bonds; or an N-oxide of said compound, wherein 1 or more N atoms carry an oxygen atom; or a pharmaceutically acceptable salt thereof; as well as to new phthalazine derivatives; processes for the preparation thereof; the application thereof in a process for the treatment of the human or animal body; the use thereof for the treatment of a disease, especially a disease caused by ocular neovascularisation, such as age-related macula degeneration or diabetic retinopathy, or other diseases that respond to the inhibition of tyrosine kinases, such as a proliferative disease; a method for the treatment of such disease in mammals; and the use of such a compound for the manufacture of a pharmaceutical preparation for the treatment especially of a disease as mentioned above.

  该发明涉及治疗炎症性疾病，特别是炎症性风湿性或风湿性疾病，以及/或疼痛的方法，该方法使用公式I,1中VEGF受体酪氨酸激酶活性抑制剂，其中r为0至2，n为0至3，R1和R2a）各自独立地为较低的烷基；b）共同形成亚式I*，2的桥，其中通过两个末端C原子实现键合，m为0至4；或c）共同形成亚式I**，3的桥，其中环成员T1、T2、T3和T4中的一个或两个是氮，其他各自为CH，通过原子T1和T4实现键合；G为—C(═O)—、—CHF—、—CF2—、较低烷基、C2-C6烯基、被乙酰氧基或羟基取代的较低烷基或C3-C6烯基、—CH2—O—、—CH2—S—、—CH2—NH—、—CH2—O—CH2—、—CH2—S—CH2—、—CH2—NH—CH2—、氧杂环（—O—）、硫杂环（—S—）、亚胺（—NH—）、—CH2—O—CH2—、—CH2—S—CH2—或—CH2—NH—CH2—；A、B、D、E和T各自独立地为N或CH，但至少一个且不超过三个为N；Q为较低烷基、较低烷氧基或卤素；Ra和Ra′各自独立地为H或较低烷基；X为亚胺、氧杂环或硫杂环；Y为氢、芳基、杂环芳基或未取代或取代的环烷基；Z为单取代或双取代的氨基、卤素、烷基、取代烷基、羟基、醚化或酯化的羟基、硝基、氰基、酯化的羧基、烷酰基、氨基甲酰基、N-单取代或N,N-双取代的氨基甲酰基、胍基、胍二氨基基、巯基、磺基、苯硫基、苯较低烷基硫基、烷基苯硫基、苯磺基、苯较低烷基磺基、烷基苯磺基，或（或者，根据该发明的更广泛方面，此外）从尿素基、卤代较低烷硫基、卤代较低烷磺基、吡唑基、较低烷基吡唑基和C2-C7烯基中选择；其中——如果存在多于1个基Z（m≥2），那么取代基Z彼此独立选择；在亚式I*中由波浪线表示的键要么是单键，要么是双键；或者是所述化合物的N-氧化物，其中1个或多个N原子携带氧原子；或其药学上可接受的盐；以及新的邻苯二氮䓬基衍生物；其制备方法；在用于治疗人体或动物体的方法中的应用；用于治疗疾病的用途，特别是由眼部新生血管形成引起的疾病，如老年性黄斑变性或糖尿病性视网膜病变，或对酪氨酸激酶抑制有反应的其他疾病，如增生性疾病；哺乳动物中治疗此类疾病的方法；以及用这种化合物制备药物制剂，特别是用于治疗上述疾病的制剂。